Overview of the Innovation in Medical Evidence Development and Surveillance (IMEDS) Program

On October 16, 2013, the Engelberg Center for Health Care Reform at Brookings hosted a webinar entitled “Overview of the Innovation in Medical Evidence Development and Surveillance (IMEDS) Program.” This webinar provided an overview of the Reagan-Udall Foundation for the FDA’s IMEDS Program and a summary of IMEDS’ development and governance structure. IMEDS will focus on developing better methods and tools for using electronic health care data for safety evaluations, including those conducted by FDA’s Sentinel Initiative; providing more educational training opportunities for scientists; and exploring additional opportunities to support safety evaluations by a broader range of stakeholders. IMEDS is a public-private partnership intended to advance regulatory science and build on the research methodologies developed under the Sentinel Initiative. Presenters included Gregory Daniel, Managing Director and Fellow at the Engelberg Center for Health Care Reform at Brookings and Senior Advisor to the Reagan-Udall Foundation; Dr. Richard Moscicki, Deputy Center Director of Science Operations, Center for Drug Evaluation and Research (CDER), FDA; and Dr. Troy McCall, Chief Implementation Officer, Reagan-Udall Foundation for the FDA.

For more information about IMEDS and other information on Brookings’ active product surveillance projects, please visit the IMEDS page and Brookings’ Sentinel project page.